Described herein are treatments and patient selection methods for cancers such as prostate cancer, breast cancer, liver cancer, bladder cancer, and melanoma. The treatment involves administering a RIPK2 inhibitor to a subject. The patient selection involves selecting a patient who has increased copy numbers or expression of both RIPK2 and MYC.